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Abstract 
Introduction: There are now a number genes, known to be associated with familial primary 
brain calcification (PFBC), causing the so called ‘Fahr's’ disease or syndrome. These are 
SCL20A2, PDGF-B, PDGFRB and XPR1. In this systematic review, we analyse the clinical 
and radiological features reported in genetically confirmed cases with PFBC. We have 
additionally reviewed pseudohypoparathyroidism which is a close differential diagnosis of 
PFBC in clinical presentation and is also genetically determined. 
Methods: We performed a Medline search, from 1st Jan 2012 through to 7th November 2016, 
for publications with confirmed mutations of SCL20A2, PDGF-B, PDGFRB, and XPR1 and 
found twenty papers with 137 eligible cases. A second search was done for publications of 
cases with Pseudohypoparathyroidism or pseudopseudohypoparathyroidism, and found 18 
publications with 20 eligible cases.  
Results: SLC20A2 was the most common gene involved with 75 out of 137 cases included 
with PFBC (55%) followed by PDGFB (31%) and PDGFRB (11%). Statistically significant 
correlation was found between the presence of parkinsonism with SLC20A2 mutations, 
headache in PDGFB and generalised tonic-clonic seizures in patients with 
pseudohypoparathyroidism.  
Conclusion: We combine statistical analysis and clinical inference to suggest a diagnostic 
algorithm based on the observations in this study to help with investigation of a patient with 
neurological features and brain calcification. 
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1. Background 
Physiological calcification in brain can be seen in up to 20% of routine CT scans [1, 2]. 
Pathological brain calcification can be due to parathyroid disorders, phacomatosis, and 
secondary to infections, inflammation or haemorrhage. Idiopathic calcification, has 
traditionally been described as ‘Fahr's disease’, based on Theodor Fahr’s report 
“IdiopathischeVerkalkung der Hirngefässe” or idiopathic calcification of cerebral vessels [3]. 
It is unlikely though that the case described in that paper was ‘primary’ and although the 
calcification was not mainly in the basal ganglia, Fahr’s name has been associated with 
primary basal ganglia calcification despite previous, possibly more accurate description by 
Delacour. The familial basis of primary brain calcification was initially suggested by Boller 
et al. who used the term familial idiopathic cerebral calcification in their 1977 paper with the 
same name[4]. The understanding of familial ‘idiopathic’ or ‘primary’ brain calcification has 
advanced dramatically in the recent years with discovery of four causative gene mutations 
namely SCL20A2, PDGF-B, PDGFRB, and XPR1 (Figure 1). There is an emerging need for a 
reappraisal of key concepts in the understanding of brain calcification. These include 
definition, familial association, nomenclature and disease phenotype that has evolved in the 
light of new genetic findings.  
Nomenclature 
The nomenclature of Fahr's disease is complicated by the fact that at least 35 names have 
been used in publications referring to brain calcification mainly limited to the basal ganglia 
[5]. “Fahr’s disease” is still the most commonly used term. A similar term “Fahr’s syndrome” 
first appeared in literature in 1982 [6] to describe the constellation of neuropsychiatric 
features and calcification. The use of term “disease” for the “primary” or idiopathic 
calcification and “syndrome” to reflect the clinical/radiological picture, when a secondary 
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cause is found, has been suggested. “Fahr’s syndrome” and “Fahr’s disease” have also been 
used interchangeably in some articles[7] and case reports[8, 9].  Some authors ascribe the 
attribution of Fahr’s name to this disorder a ‘misnomer’[5]. The other names for the same 
syndrome have been used to reflect location or aetiology such as ‘primary’ or ‘idiopathic’ 
brain calcification. These include bilateral striatopallidodentate calcification or calcinosis 
(BSPDC) and idiopathic basal ganglia calcification (IBGC) respectively [5]. Considering the 
complicated terms used to describe location of the calcification, the term primary familial 
‘brain’ calcification (PFBC) has been proposed[10] to replace other terms used such as Fahr's 
disease and IBGC.[10] For the purpose of the search and analysis we have included a broad 
range of terms used to describe cases with brain calcification, including “Fahr’s disease” and 
“Fahr’s syndrome” but for purpose of discussion we prefer to use PFBC which is more 
contemporary to current literature on the subject [11].  
The causes of brain calcification include disorders of parathyroid such as 
hypoparathyroidism. Some cases with brain calcification are due to other metabolic 
disturbances [12-15].  Hypoparathyroidism characterized by parathyroid hormone (PTH) 
deficiency leads to impaired calcium metabolism and has been linked to brain calcification. 
In cases with pseudohypoparathyroidism and pseudopseudohypoparathyroidism the 
Parathyroid glands produce PTH but the uptake of PTH is impaired. Both 
pseudohypoparathyroidism and pseudopseudohypoparathyroidism have been linked to 
mutations in GNAS and STX16. There have been very few reports of genetically determined 
pseudohypoparathyroidism and pseudopseudohypoparathyroidism. There may be other yet 
unidentified genetic causes of pseudohypoparathyroidism and 
pseudopseudohypoparathyroidism and it is possible that not all are caused by GNAS and 
STX16 mutations. The clinical manifestations of these are quite like the cases reported as 
Fahr’s syndrome or PFBC; such as progressive movement disorders with or without cognitive 
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decline and psychiatric features. The characteristic metabolic profile associated with 
hypoparathyroidism is not seen and cases with pseudohypoparathyroidism do not have 
reduced PTH levels and are difficult to detect clinically. However, one may suspect 
pseudohypoparathyroidism clinically, based on some characteristic skeletal changes, 
particularly in the fingers but genetic testing is needed to confirm the diagnosis. Conversely, 
some other neuro-genetic and disorders with DNA repair defects that are associated with 
basal ganglia calcification but manifest clinical features or demographic profile that is quite 
unlike PFBC. One such example is Aicardi-Goutières Syndrome which is an early-onset 
encephalopathy characterized by basal-ganglia calcification, white matter abnormalities, and 
a chronic cerebrospinal fluid (CSF) lymphocytosis and is characterized by an interferon 
signature [16]. We included cases with pseudohypoparathyroidism which most closely 
resemble PFBC in our analysis mainly for differential diagnosis but the cases with 
phacomatosis, DNA repair defects and hypoparathyroidism were excluded.  
Pathophysiology of genetically determined brain calcification 
With the discovery of new genes for basal ganglia calcification the understanding of 
mechanisms of calcification has improved significantly. This understanding though is far 
from complete. Calcium, like most minerals has quite complex metabolism in human cells 
and pathogenesis of the brain calcification related to the four reported genes is incompletely 
understood. A summary of this understanding is presented below. 
Located at 8p11.21, the Solute Carrier family 20 (Phosphate Transporter), Member 2 or the 
SLC20A2 gene encodes the type III sodium-dependent inorganic phosphate (Pi) transporter 2 
(PiT2) [17]. Mutations in SLC20A2 are inherited in an autosomal dominant manner. 
Inorganic phosphate transport is crucial to cellular calcium and phosphate homeostasis and 
the impairment in the function of PiT2 [17] can contribute to the deposition of calcium 
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phosphate in the vascular extracellular matrix [18].  Although calcification is limited to brain 
in cases reported with SLC20A2, its role of in homeostasis for inorganic phosphate is evident 
in several other tissues around the body including bone, parathyroid, and kidneys [19, 20]. 
The pathophysiology of calcification associated with SLC20A2 has been studied using 
Slc20a2-knockout (KO) mice. Slc20a2-KO mice indeed have a high CSF [Pi] which supports 
a role of PiT2 in Pi export from the CSF as one of the mechanisms with possible therapeutic 
implications[21].  
Xenotropic and Polytropic Retrovirus receptor or XPR1gene is located at 1q25.3. In 
families,the mutations are inherited  as autosomal dominant. The gene is closely linked to 
PiT2, encoding a retroviral receptor with a role in phosphate export from the cells [18]. It 
directly affects phosphate homeostasis intracellularly and dysfunction of this mechanism can 
contribute to calcium deposition.  
PDGFRΒ is another gene implicated in PFBC encodes for one of the two receptors for 
platelet-derived growth factor (PDGF) with subunit ß (PDGFB), its major ligand. PDGFRΒ 
is crucial in maintaining the blood brain barrier (BBB) and loss of function mutations can 
potentially lead to altered permeability in pericytes surrounding the brain blood vessels that 
can potentially lead to calcium deposition [22-24]. Mutations in both PDGFB and PDGFRB 
have autosomal dominant mode of inheritance. The PDGFB is involved in pericyte 
recruitment, Blood brain barrier (BBB) regulation and angiogenesis [25].  Loss of calcium 
regulation through the BBB possibly leads to progressive calcinosis [25]. It has also been 
proposed that the PDGF proteins can have regulatory functions on phosphate transporters 
XPR1 and PiT in the brain [23]. The possible interactions between the mechanisms of 
calcium deposition related to PiT2, pericytes and BBB remain to be elucidated.  
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Brain calcification can also be seen in disorders with PTH resistance. Loss of function of 
GNAS (also known as Guanine Nucleotide Binding Protein (G Protein), Alpha Stimulating 
Activity Polypeptide 1) on the maternal allele is known to cause basal ganglia calcification 
though this is not considered as PFBC. GNAS is a complex imprinted locus that produces 
multiple transcripts through alternative splicing and promoters [26].  GNAS mutations can 
result in a group of pseudohypoparathyroid disorders which include 
pseudohypoparathyroidism type Ia, pseudohypoparathyroidism type Ic, 
pseudopseudohypoparathyroidism and McCune-Albright syndrome.  
Pseudohypoparathyroidism type Ib is usually due to imprinting/methylation defects in GNAS 
mentioned above leading to loss of function on the maternal allele but can also be seen due to 
STX16 mutations [27]. These disorders are known to have distinct clinical features such as 
brachydactyly, short stature, skeletal abnormalities (except in Pseudohypoparathyroidism 
type Ib) [28]. This distinction is mainly driven by the understanding that in cases with 
pseudohypoparathyroidism type 1a with loss of function in GNAS, there is generalized 
hormonal resistance to parathyroid hormone (PTH), TSH and gonadotrophins.  
With the clear differences in the genetic pathomechanisms it is reasonable to expect some 
differences in the clinical features of patients with different genetic mutations. Here in this 
systematic review we review the clinical presentations in the genetically confirmed PFBC 
and pseudohypoparathyroidism which is a close differential diagnosis.  
2. Methods 
Systematic review of the literature was performed per the PRISMA guidelines (Preferred 
Reporting Items for Systematic Reviews and Meta-analyses). The first search included all 
publications in English from 1st Jan 2012 (when genes for PFBC were discovered) through to  
7th November 2016. The following search terms were applied: Brain calcification, cerebral 
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calcification, fahr* disease, fahr* syndrome, idiopathic basal ganglia calcification, primary 
familial basal ganglia calcification, bilateral striatopallidodentate calcification OR calcinosis, 
IBGC OR PFBC OR BSPDC AND SLC20A2, PDGFB, PDGFRΒ OR XPR1. Inclusion 
criteria included a positive genetic test result of SLC20A2, PDGFB, PDGFRΒ or XPR1 
mutation and brain calcification seen on CT or MRI. 
We carried out a second search that included all publications in English up until 7th 
November 2016 using search terms: Pseudohypoparathyroid*, 
pseudopseudohypoparathyroid*, GNAS* OR STX16; AND brain calcification OR cerebral 
calcification. Inclusion criteria for a study were clinically confirmed 
pseudohypoparathyroidism, brain calcification seen on neuroimaging, normal parathyroid 
testing with or without confirmed GNAS mutation. We excluded phacomatosis, DNA repair 
defects and cases with brain calcification due to other secondary causes. 
Demographic data, including age at onset, duration, sex, clinical features at presentation, 
radiological features on available neuroimaging and blood investigations (parathyroid 
hormone and calcium) were recorded when available in cases with a genetic diagnosis. 
Statistical analysis of associations between demographic, clinical and radiological 
characteristics of SLC20A2, PDGFB, PDGFRΒ, XPR1 and pseudohypoparathyroidism was 
performed using IBM SPSS (version 20). Continuous data was compared between groups 
using two-tailed t-tests (two groups). Comparison of categorical data was performed with 
Pearson Chi2 analysis; threshold for all statistical significance was p < 0.05. This article does 
not contain any studies with human or animal subjects performed by any of the authors. 
 
3. Results 
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We identified 20 publications which satisfied the inclusion criteria [17, 18, 22, 23, 29-44] for 
review (Supplementary figure). We collated information on 137 cases, either sporadic or 
from 34 families, with demographic and clinical characterisation found in Table 1. To further 
investigate the hypothesis that pseudohypoparathyroidism represents a comparable phenotype 
as a form of genetic brain calcification, we identified 18 publications with data on 20 patients 
which satisfied the inclusion criteria for review [12, 15, 45-60]. Apart from two families with 
two affected individuals in each, all cases of pseudohypoparathyroidism with cerebral brain 
calcification present were reported as sporadic. There were no clinical reports of 
pseudopseudohypoparathyroidism secondary to GNAS mutations within the search 
parameters. 
 3.1. Demographic characteristics and information availability 
SLC20A2 was the most common gene involved with 75 out of 137 cases included with PFBC 
(55%) followed by PDGFB (31%) and PDGFRB (11%) (Table1). Only 53.5% patients with 
PFBC had a clearly recorded age of onset. Age at presentation was better recorded with rate 
of 91% across all cases. The details of PFBC cases and the comparison with 
Pseudohypoparathyroid cases are presented in Table 1.  
3.2. Clinical phenotype and distinctive clinical features  
The breakdown of clinical presentation for symptomatic patients, divided into neurological or 
psychiatric presentation is presented in Table 2.  Individual clinical symptoms are presented 
in Table 2 and Figure 2. Almost a quarter (24%) of cases in the studies included was 
asymptomatic.  
Through group-wise, then individual-wise analysis, we identified certain clinical features 
occurred significantly more frequently with a genetic abnormality compared to the other 
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mutations combined (Chi2 analysis, p <0.05). Thus, parkinsonism was more commonly 
observed in SCL20A2 (21% of cases) and headache was more common in PDGFB (32.5% of 
cases). Generalised tonic-clonic seizures (GTCS) were significantly more in 
pseudohypoparathyroidism (65% of cases).   
Parkinsonism was seen in 16% of all the included cases; however, the details of specific 
parkinsonian features were sparse. Hyperkinetic movement disorders were reported seen in 
20% though a breakdown of hyperkinetic movement disorder was not available in all the 
cases (details in Figure 2).  
Cognitive impairment was seen in 15% of all the cases and although 67% of XPR1 cases had 
cognitive impairment, this difference did not reach statistical significance. Depression was 
the most frequent psychiatric feature in 7% of all cases and present in 33% of PDGFRB cases 
but statistical analysis showed that frequency of depression, and other psychiatric features, 
was comparable across the groups (p>0.05). 
3.3. Radiological phenotype and distinctive features  
Basal ganglia calcification was present in all of cases with the PFBC and gene mutations but 
this was not true for pseudohypoparathyroidism as 95% had calcification of the basal ganglia. 
Other areas that reported cerebral calcification include the thalamus, cerebellum (and 
specifically dentate nucleus), subcortical grey matter or grey-white junction and cortical areas 
(Figure 2). The thalamus and dentate nucleus was significantly more frequently reported as 
an area of brain calcification in SCL20A2 cases compared to other mutations combined when 
tested with Chi2 analysis (p <0.05). This result may be affected by reporting bias, which will 
be discussed below. All other areas of cerebral calcification are comparable across all 
mutation groups (p>0.05) but only PDGFB mutations were noted to have cysts in the white 
matter with leucodystrophy like presentation in 2 cases[61]. 
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4. Discussion 
We discuss here the results from this analysis and summarize the current information for each 
genetic cause of PFBC and pseudohypoparathyroidism. It has been suggested that clinical 
features among the commonly reported mutations were psychiatric signs (72.7%, 76.5%, and 
80% for PDGFB, SLC20A2, and PDGFRB, respectively), movement disorders (45.5%, 
76.5%, and 40%), and cognitive impairment (54.6%, 64.7%, and 40%)[62].  
SLC20A2  
With regards to age of onset, SCL20A2 cases were older than PDGFRB and 
pseudohypoparathyroid cases (38.6 vs. 25.3 and 20.1). This observation is limited by the fact 
that there is only 54.3% data availability for age of onset. Although presentation with 
hyperkinetic movement disorders is characteristic of all genetic forms of PFBC, parkinsonism 
(21%) was significantly more common with SCL20A2 mutations. However, details of 
parkinsonian features regarding presence of tremor, bradykinesia or gait disorder were not 
always mentioned. There is marked heterogeneity in presentation, including not otherwise 
specified “hyperkinetic movement disorder” (19%), dystonia (13%), chorea (12%), and 
cerebellar ataxia (8%). In the newly redefined IBGC2 kindred linked to SLC20A2, gait and 
upper limb ataxia, slurred speech, hyperreflexia, intellectual impairment has been 
described[42]. Depression appears to be the most common psychiatric features though 
anxiety, agitation, psychosis, has been also reported in small number of cases. Headache has 
been reported in a small number of cases without a clearer classification of the headache 
characteristics. Involvement of thalamus and dentate nucleus was significantly more frequent 
in SCL20A2 cases than in other genetic PFBC on imaging. Thus, patients with late onset 
movement disorder with signs of parkinsonism and calcification in basal ganglia, thalamus 
and dentate are possibly best candidates to be screened for this mutation.  
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PDGFB 
The mutations in the PDGFB gene are the second most common cause of PFBC. Clinically, 
cases reported with PDGFB mutations have hyperkinetic movements (19%) (not further 
specified), dystonia (9%), chorea (14%) and ataxia (14%) which appeared more commonly 
than parkinsonism (7%) and seizures (5%). This difference did not reach statistical 
significance which could be due to heterogeneity of the clinical description of hyperkinetic 
movement disorders. Similar to other genetic mutations, basal ganglia and cerebellum are 
commonly calcified. Subcortical calcification is relatively common (47%) and one of the 
reported cases have cortical calcification. The cases with PDGFB mutations have been most 
commonly described to have headache (29%) (p<0.05). The implications of this are discussed 
in greater detail below.  
PDGFRΒ  
There is limited number of cases published with clinical details on cases with abnormalities 
in PDGFRB gene. The age of onset and age at presentation is earliest compared to other 
mutations. Headache and depression seemed commoner in this group but this finding did not 
reach statistical significance. More studies are needed to better understand characteristics of 
this group. 
XPR1 
Recently, mutations in the XPR1 gene have been identified as a cause of PFBC. XPR1 
mutations seem to present with higher incidence of cognitive dysfunction (66.7%) and 
cortical calcium deposition (Figure 2). Parkinsonism, dysarthria and chorea have been seen 
but no cases have been reported with headache, dystonia or cerebellar ataxia. More studies 
are needed to better understand characteristics of this group. 
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Pseudohypoparathyroidism 
In comparison to PFBC cases, these cases had a higher likelihood of seizures (GTCS) and a 
notable absence of reported psychiatric features and headache. The reason for including this 
group in our study and analysis is supported by the overall similarity in neurological 
presentation of these cases to genetically determined PFBC as there was no statistically 
significant difference in movement disorders and cognitive changes between PFBC and 
pseudohypoparathyroidism.  There was a trend of higher frequency of hyperkinetic 
movement disorders in comparison to parkinsonism but that was not statistically significant 
However, recognition of seizures as a key clinical feature may help differentiating this 
disorder when investigating families or sporadic cases with brain calcification and 
neurological features. It is known that hypocalcaemia is one of the causes of seizures specific 
to this group [45], but low calcium levels were not recorded as the cause of seizures in most 
of the reported patients included in this study. The cases with pseudohypoparathyroidism 
differ from hypoparathyroidism in many ways such as levels of PTH and calcium and 
presence of skeletal abnormalities. The absence of psychiatric features in this group is 
interesting, considering that psychiatric complaints are well documented in the literature for 
cases of hypoparathyroidism and other parathyroid disorders. It may be worthwhile 
separating this group out from the parathyroid disorders considering the pathomechanism, 
genetic mutations and clinical features for better identification in clinic and research studies.  
PFBC with no known mutations 
Nicolas et al reported clinical and radiological profile of 47 cases with no mutations in 
PDGFRB or SLC20A2 [62]. The cases with no mutations seemed to have a higher chance of 
seizures and considering our observation in pseudohypoparathyroidism cases, screening all 
cases with PFBC for this condition may be a useful. Overall the clinical and radiological 
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features of these cases were quite like the cases with genetically confirmed mutations in 
SLC20A2 or PDGFRB [62].  
Not all cases with PFBC have mutations and the figures vary but up to 65% cases may not 
have a known mutation [62]. There may be two reasons for this. Firstly, it may be possible 
that there are still unidentified mutations that are responsible for PFBC. Secondly, it is 
possible that there has been some inconsistency in how the genes have been tested. For 
example, the identification that IBGC 1 and more recently IBGC2 loci map to SLC20A2, 
supports the idea that clinical identification is very important [42]. We did not include the 
PFBC cases without mutations in our study which was mainly to help identify the phenotypic 
genotypic association, but it comparing the clinical and radiological findings between 
mutation carriers and non-mutation carriers with PFBC might be useful. Grutz et al., have 
proposed and tested an algorithm based on sites of calcification and individual’s age to 
predict the chances of positive genetic finding in PFBC [42]. They divided the brain into four 
sites defined as follows: i) basal ganglia (including the caudate nucleus, putamen, and globus 
pallidus), ii) thalamus and subthalamic nucleus iii) cerebellum, and iv) cortical region and 
suggest that presence of  
i) At least one site with bilateral calcification in individuals between 20 and 40 years 
of age, and  
ii) At least two sites with bilateral calcification in individuals between 41-70 years of 
age [62].  
Together with this algorithm, which helps identify the positive genetic cases, the algorithm 
we propose below enhances the possibility of finding the right gene based on the clinical 
features.  
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Analysis 
Here we confirm and extend previous descriptions including a comprehensive review of a 
large patient cohort with SCL20A2 or PDGFRΒ mutation by the French IBG group.[63] 
Tadic et al. (2015) performed a similar systematic, thorough review of SCL20A2, PDGFB 
and PDGFRΒ cases, but not the XPR1 mutation, discussing the need for more robust and 
uniform data-collection in future PFBC cases. There are some small differences in frequency 
of clinical features reported in both studies compared to this systematic review and likely 
represent different patient selection. 
This study has some limitations and we acknowledge the potential errors of genotype-
phenotype characterisation using systematic review but feel it is a robust technique when 
reviewing such rare diseases. This method should be used to continually update our clinical 
knowledge as new cases are discovered and more data can be included in analysis. We 
support previous suggestions for a more uniform reporting style with key clinical data fields 
included in future research studies. The low number of cases for certain mutations, including 
XPR1 and pseudopseudohypoparathyroidism, is a form of statistical bias. Selection bias is 
another avenue for error within a systematic review. [11, 64]  
It has been suggested that the functional abnormalities leading to movement disorders, 
cognitive and psychiatric features in brain calcification probably result from the disruption of 
the basal ganglia-thalamocortical circuits.[65] In terms of genotype-phenotype correlation, 
one may hypothesise that the clinical presentation can vary depending on location of calcium 
deposits (e.g. striatum, cortical areas or dentate nucleus). This correlation does not seem 
absolute. There has been at least one study using [18F] FDG-PET that found areas of cortical 
hypometabolism, in the areas that did not have calcifications or other morphological changes 
and this correlated to the patient’s neuropsychological symptoms [29]. It is therefore 
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plausible that calcium deposition may not be the only pathophysiological mechanism in 
patients with the genetic mutations and highlights the importance of future studies 
investigating asymptomatic patients.  
It has been noted that patients with the PDGFB mutations had headache. However, on closer 
analysis, this symptom did not co-segregate in most of the families suggesting an absence of 
causal relationship. There is quite marked clinical heterogeneity of familial PFBC cases and 
~40% of the patients carrying basal ganglia calcification did not show any symptoms as 
reported on a large case series[66]. 
Although this co-segregation may be incidental, or reflective of data collection (selective 
bias), one may bear in mind that calcium and parathyroid abnormalities have been recorded 
in patients of headache with Idiopathic intracranial hypertension (IIH) [67, 68]. In one study 
ten percent of IIH patients had abnormalities in calcium (Ca) serum level: six had 
hypocalcemia and 1 had hypercalcemia[68]. A better documentation of calcium, parathyroid 
hormone status and CSF pressure or at least fundus examination might help with better 
characterization of headaches in genetic mutations leading to brain calcification.  
There are some key limitations in the current understanding of brain calcification that this 
review highlights. Interestingly none of the genes involved in the calcium metabolic pathway 
have been described as a cause of the PFBC syndrome [69].  Phosphate transport seems to be 
an important part of the process of calcification in PFBC.  SLC20A2 gene encodes type III 
sodium-dependent inorganic phosphate (Pi) transporter 2 (PiT2)[17] and the impairment in 
the function of PiT2 [17] can contribute to the deposition of calcium phosphate in the 
vascular extracellular matrix [18].  A recent study in Slc20a2-knockout (KO) mice 
demonstrated high CSF [Pi]. The hyperphosphatemia in CSF possibly reflects impaired 
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phosphate export from the CSF [21]. These studies support a pathophysiological link between 
SLC20A2 mutations and defective phosphate transport that might be responsible for PFBC.  
XPR1 also closely links to PiT2 [18] and considering the observation of CSF increase of 
phosphate in Slc20a2-knockout animal models, it is quite likely that impairment in the 
function of PiT2 and inorganic phosphate (Pi) transport is the main cause of PFBC at least in 
IBGC 1, 2, 3, and 6.  
PDGFRΒ is another gene implicated in PFBC encodes for one of the two receptors for 
platelet-derived growth factor (PDGF) with subunit ß (PDGFB), its major ligand. PDGFB is 
a cell-surface tyrosine kinase receptor, which plays an essential role in various signalling 
pathways involved in the regulation of cell proliferation, differentiation, survival, and 
migration. The PDGF in the endothelial cells and pericytes seem to have a different 
mechanism of action with the same consequence of calcium deposition around the blood 
vessels in brain[70].  It has been proposed that the integrity of the BBB is compromised in 
PDGFRB, which secondarily induces vascular and perivascular calcium depositions [22]. In a 
study of the correlation between calcification induced by Pi, PDGF-BB was shown to 
increase the expression of PiT-1 in the endoplasmic reticulum in primary cultures of rat aortic 
vascular smooth muscle cells. This could thereby mediate an increase in the Pi influx into the 
smooth muscle cell, therefore facilitating the formation of calcium phosphate deposits in the 
new generated matrix vesicles[71]. Although PiT1 is possible more in abundance in the 
vascular endothelium and possibly equally ore more important for phosphate transportation, 
interestingly, SLC20A1 gene, which codes for the phosphate transporter 1 (PiT1), has been 
screened but not been found in PFBC patients [69]. 
 
The calcium deposition in PFBC starts in the endothelial and smooth muscle cells of blood 
vessels in the Globus pallidus which are most susceptible to build calcium deposits in 
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response to various metabolic triggers [72]. Calcifications limited to Globus pallidum can be 
also be linked to ageing and are prevalent in people over 60 years of age (5.5–20 %)[2]. 
Drawing from some studies on vascular smooth muscle cells and aortic valve calcification, 
hyperphosphatemia is an important contributor to vascular calcification [72, 73]. Elevated 
phosphate induces calcification of smooth muscle cells (SMC) in vitro and inhibition of 
phosphate transport by phosphonoformic acid blocks phosphate-induced calcification, 
implicating sodium-dependent phosphate cotransporters (PiT 1 and PiT 2) in this process. 
This can have potential therapeutic implications considering that Slc20a2-knockout (KO) 
mice have already been shown to have hyperphosphatemia in the CSF.  
It seems that there is interplay of the genetic factors contributing to calcium deposition but 
more experimental work is needed to understand this.  
5. Conclusion 
Our analysis of genotype-phenotype correlation in brain calcification related to genetic 
mutations suggests that although there is significant overlap in terms of clinical and 
radiological features, there may be certain features significantly associated with specific 
mutations.   
With regards to significant distinctive neurological features, parkinsonism was more common 
with SLC20A2 mutations, headache with PDGFB and generalised tonic-clonic seizures were 
seen in pseudohypoparathyroidism. Radiologically, calcification of the thalamus was 
significantly more common with SCL20A2 mutations. 
Some features that differed across groups were not statistically significance however we feel 
the association may still be noteworthy. For example, with regards to psychiatric features, 
depression was more often reported in PDGFRB (p>0.05). Cognitive impairment and 
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parkinsonism tended to occur with late onset of disease (>45 years) while younger onset 
cases more commonly had hyperkinetic movement disorders such as chorea and dystonia. 
Like other neurodegenerative conditions it is possible that patients with PFBC may have 
different clinical presentation at different ages with the same pathological process.  
In summary, using systematic review we have identified several distinct features which may 
aid the clinical diagnostic process. Based on the existing knowledge (figure 3a) and 
observations made in this analysis we propose a schematic plan (figure 3b) to investigate 
patients with brain calcification and neurological or psychiatric features.    
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Legend for figures:  
Figure 1a Simple schematic representation of mechanisms responsible for brain calcification  
Figure 1 b Schematic representation of the postulated mechanisms in genetically mediated 
microvascular calcium deposition in the brain. The scheme shows a cross section through a 
blood vessel in the brain demonstrating the location of pericytes and neural tissue. PDGF B 
and PDGF RB are located in the pericytes and loss of gene function can cause age-dependent 
phenotypic change in pericytes that ultimately provokes the formation of microvascular 
calcification. Phosphate uptake through the inorganic phosphate transporter type III is 
impaired in SLC20A2 and XPR1 mutations. Parathormone uptake is facilitated through G 
Protein coupled cyclic AMP activity which can be lost in GNAS1 mutations.    
PiT2 – inorganic phosphate transporter 2, PTH- Parathormone  
Figure 2 Histogram showing (A) clinical presentation by category (neurological, psychiatric 
or asymptomatic), (B) psychiatric presentation by symptom, and (C) neurological 
presentation by symptom. (D). Histogram showing calcification on CT head imaging by 
anatomical location.   
Genetic mutations leading to cerebral calcification present with neurological symptoms more 
frequently than psychiatric symptoms or being asymptomatic. Depression is the most 
common psychiatric symptom. Parkinsonism (14.7%), a hyperkinetic movement disorder 
(20.5%) and cognitive impairment (13.9%) were the most frequent neurological symptoms 
across all mutations. GTCS, parkinsonism and headache were associated with 
Pseudohypoparathyroidism, SLC20A2 and PDGFB mutations, respectively, at statistically 
significant higher frequency compared to other mutations combined when tested with 
Chi2 analysis (« indicating p <0.05). Note that chorea and dystonia represent further 
breakdown of the hyperkinetic movement disorder category. 
Basal ganglia calcification is most consistently observed (99.26% of all cases). Cerebellar 
calcification is the next most frequently calcified area across all mutations (50% of all cases). 
Dentate nucleus calcification is described with SCL20A2 mutations at statistically significant 
higher frequency compared to other mutations combined (*p <0.05). 
CT – computerised tomography GTCS = generalised tonic clonic seizures 
  
Figure 3a. Causes of brain calcification 
Figure 3b. Schematic plan of investigation of brain calcification. 
Supplementary figure 1 Search strategy and included studies. 
 
 
